In the EMPA‐REG OUTCOME trial, we explored the association between pre‐randomization uric acid level tertile (<309.30 μmol/L; 309.30 to <387.21 μmol/L; ≥387.21 μmol/L) and cardiovascular (CV) death, hospitalization for heart failure (HHF), HHF or CV death, all‐cause mortality, three‐point major adverse CV events (MACE), and incident or worsening nephropathy. Patients with type 2 diabetes and CV disease received empagliflozin or placebo. The median baseline plasma uric acid level was 344.98 μmol/L, and patients’ baseline characteristics were mainly balanced across tertiles. Baseline uric acid levels were associated with cardio‐renal outcomes: in the placebo group, for the highest versus lowest tertile, the multivariable hazard ratios for three‐point MACE, HHF or CV death, and incident or worsening nephropathy were 1.22 (95% confidence interval [CI] 0.89–1.67; P = 0.2088), 1.51 (95% CI 1.02–2.23; P = 0.0396) and 1.77 (95% CI 1.33–2.34; P  < 0.0001), respectively. When tested as a continuous variable, baseline uric acid was associated with all outcomes in the placebo group. Empagliflozin improved all cardio‐renal outcomes across tertiles, with all interaction P values >0.05. Further investigation of these relationships is required.

中文翻译：

---

尿酸水平与 2 型糖尿病患者心肾结局和死亡之间的关联：EMPA-REG OUTCOME 的亚分析。


在 EMPA-REG OUTCOME 试验中，我们探讨了随机分组前尿酸水平三分位数 (<309 id=7>P = 0.2088)、1.51 (95% CI 1.02–2.23； P = 0.0396) 和 1.77 (95% CI 1.33–2.34； P < 0.0001）。当作为连续变量进行测试时，基线尿酸与安慰剂组的所有结果相关。恩格列净改善了三分位数的所有心肾结局，所有交互作用P值均>0.05。需要进一步调查这些关系。